Other Events ·
On June 29, 2026, NeuroSense Therapeutics announced that its Phase 2b study for Amyotrophic Lateral Sclerosis (ALS)…
NRSNNeuroSense Therapeutics Ltd.
On June 29, 2026, NeuroSense Therapeutics announced that its Phase 2b study for Amyotrophic Lateral Sclerosis (ALS) achieved its primary endpoint, demonstrating a statistically significant reduction of TDP-43, a defining pathological hallmark of the disease. The company incorporated the results into several existing Registration Statements on Form S-8 and Form F-3. NeuroSense Therapeutics is a biotechnology company developing therapeutics for neurological disorders.